Form 4: Aadi Bioscience CEO David Lennon Executes Stock Options, Sells Shares to Cover Taxes
SEC Form 4 Filing
Aadi Bioscience CEO David Lennon exercised stock options and sold a portion of the acquired shares to cover tax obligations.
Summary
- On October 2, 2024, David James Lennon, CEO of Aadi Bioscience, Inc., exercised 32,558 restricted stock units (RSUs) that vested on the same day.
- Following the exercise, on October 3, 2024, Lennon sold 9,689 shares of common stock at a price of $1.94 per share.
- The sale was executed to satisfy tax withholding obligations related to the vesting of the RSUs.
- After the transactions, Lennon directly owns 22,869 shares of Aadi Bioscience common stock.
- Lennon has also granted a Power of Attorney to several individuals to handle SEC filings related to company securities.
Sentiment
Score: 5
Explanation: This is a neutral document detailing routine stock transactions by the CEO. It doesn't inherently indicate positive or negative sentiment about the company's performance.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
This is a routine SEC filing related to insider transactions. It is common for executives to exercise stock options and sell a portion of the shares to cover tax liabilities. These transactions are closely monitored by investors for insights into management's sentiment about the company's prospects.
Comparison to Industry Standards
- Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
- The sale of shares to cover tax obligations is a standard practice among executives who receive equity compensation.
- Similar transactions are regularly reported by executives at comparable companies in the biotechnology sector, such as Mirati Therapeutics and Relay Therapeutics.
Stakeholder Impact
- The sale of shares by the CEO could have a minor impact on the stock price in the short term, but the overall impact is likely to be minimal.
Key Dates
| Date | Description |
|---|---|
| 10/02/2024 | Date of Power of Attorney execution and RSU vesting and exercise. |
| 10/02/2024 | CEO exercised 32,558 restricted stock units (RSUs). |
| 10/03/2024 | CEO sold 9,689 shares of common stock at $1.94 per share. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.